Program Status
RecruitingPhase
Phase 1Prior Immunotherapy Allowed
YesCRC-directed Trial
YesTags
MSI-H/ MMRd, MSS/ MMRpComments
Trial with preliminar good result in CRC, only in Australia.
Nov 2018: “Of the 5 subjects evaluable for assessment of anti-tumour activity, one with microsatellite stable (MSS) mCRC had a partial response (PR) with an 86% reduction in the size of target lesions at the 26-week scan”
NCT ID
PG545 (pixatimod) in combination with nivolumabDate Trial Added
2019-04-26Updated Date
2019-07-29